Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years old~* Creatinine clearance (Ccr) \< 15 ml/min/1.73 m2~* Anti-HCV (Abbott HCV EIA 3.0, Abbott Diagnostic, Chicago, IL) positive \> 6 months~* Detectable serum quantitative HCV-RNA (Cobas Taqman HCV test, version 2, Roche Diagnostics) with a dynamic range of 25-391000000 IU/ml~Exclusion Criteria:~* Receiving interferon-based therapy for chronic hepatitis C~* Severe anemia (hemoglobin \< 10 g/dL) or hemoglobinopathy~* Neutropenia (neutrophil count, \<1,500/mm3)~* Thrombocytopenia (platelet \<90,000/ mm3)~* Co-infection with HBV or HIV~* Chronic alcohol abuse (daily consumption \> 20 g/day)~* Autoimmune liver disease~* Decompensated liver disease (Child classification B or C)~* Neoplastic disease~* An organ transplant~* Immunosuppressive therapy~* Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases, psychiatric diseases, neurological diseases, diabetes mellitus~* Evidence of drug abuse~* Unwilling to have contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Peginterferon alfa-2a and ribavirin (Type: EXPERIMENTAL): Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
- Peginterferon alfa-2a (Type: EXPERIMENTAL): Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).